Other Information.
−Removed: On November 11, 2020, our Board of Directors (the “Board”) approved the terms of the First Amended Executive Employment Agreement, by and between Saiid Zarrabian and Kintara Therapeutics, Inc., including (i) that Mr.
−Removed: Zarrabian will be eligible to receive an annual (fiscal year) performance bonus of up to fifty percent (50%) of his base salary, subject to the achievement of performance targets or criteria established by the Board for such year in consultation with Mr.
−Removed: Zarrabian and (ii) that in the event of overachievement of such targets or criteria for a given fiscal year, the Board may increase the bonus for such year to up to an additional twenty-five percent (25%) of Mr.
−Removed: Zarrabian’s base salary.
−Removed: In addition, on November 11, 2020, the Board approved the acceleration of vesting of 279,675 stock options to purchase shares of our common stock previously granted to Mr.
−Removed: Zarrabian on September 5, 2019, and which have an exercise price of $0.61 per share.
+Added: On February 11, 2021, upon recommendation by the Compensation Committee, the Board approved the payment of retention bonuses of $56,000 to John Liatos and $41,250 to Steve Rychnovsky.
+Added: The retention bonuses will be payable on the first business payment cycle following the end of our 2021 fiscal year, or earlier upon Board discretion.
+Added: On February 11, 2021, upon recommendation by the Compensation Committee, the Board approved the modification of the Company’s vacation policy from an accrual-based policy to an unlimited policy, which eliminates the need for an accounting liability for accrued vacation.
First Amended Executive Employment Agreement, by and between Kintara Pharmaceuticals, Inc.
−Removed: and Saiid Zarrabian†
+Added: and Saiid Zarrabian (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q filed with the SEC on November 12, 2020)†
Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
13 unchanged sentences
Kintara Therapeutics, Inc.
−Removed: November 12, 2020
+Added: February 12, 2021
/s/ Saiid Zarrabian
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 12, 2020
+Added: February 12, 2021
/s/ Scott Praill
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.